IP Library Granted Patent US 12662551
Granted Patent B2
US 12662551 · App. 17/779,608 · Granted Jun 23, 2026

Monoclonal antibody for detection of CAR-T cells, kit and application

Inventors: Liang Da (Suzhou, CN); Guowei Wei (Suzhou, CN); Xin Chen (Suzhou, CN); Dongge Feng (Suzhou, CN); Wei He (Suzhou, CN); Xuejun Yu (Suzhou, CN)
Assignee: BIOSWAN LABORATORIES, CO., LTD.
C07K16/42G01N33/56966G01N33/56972G01N33/577C07K2317/565C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12662551
App. No.
17/779,608
Granted
Jun 23, 2026
Kind
B2
Abstract

A monoclonal antibody used for specifically binding to CAR molecules, which is characterized in that the monoclonal antibody comprises a light chain and a heavy chain, the light chain comprises CDR regions having an amino acid sequence as shown in SEQ ID NO: 1-3, and the heavy chain comprises CDR regions having an amino acid sequence as shown in SEQ ID NO: 5-7. By using the described monoclonal antibody or a CAR-T cell detection kit, the steps of CAR-T cell detection are simple, detection time is short, and the detection results are stable. An anti-FMC63 ScFv antibody can reduce the cost of detecting universal anti-CD19 CAR-T cells.

Claims (9)

1 . A monoclonal antibody specifically binding to a chimeric antigen receptor (CAR) molecule, which comprises a light chain and a heavy chain, wherein the light chain and the heavy chain comprise light chain variable regions (VL) and heavy chain variable regions (VH) which comprise the complementarity determining regions (CDR), wherein the light chain variable region comprises a VL CDR1 having an amino acid sequence as shown in SEQ ID NO: 1, a VL CDR2 having an amino acid sequence as shown in SEQ ID NO: 2, and a VL CDR3 having an amino acid sequence as shown in SEQ ID NO: 3, and the heavy chain variable region comprises a VH CDR1 having an amino acid sequence as shown in SEQ ID NO: 5, a VH CDR2 having an amino acid sequence as shown in SEQ ID NO: 6, and a VH CDR3 having an amino acid sequence as shown in SEQ ID NO: 7.

2 . The monoclonal antibody specifically binding to a CAR molecule according to claim 1 , which comprises one or more of the following features:

1) the light chain variable region has an amino acid sequence as shown in SEQ ID NO: 4; and

the heavy chain variable region has an amino acid sequence as shown in SEQ ID NO: 8;

2) the monoclonal antibody is murine-derived;

3) the monoclonal antibody is a subtype selected from the group consisting of IgG1, IgG2a, IgG2b, IgG2c and IgG3.

3 . The monoclonal antibody specifically binding to a CAR molecule according to claim 1 , wherein the light chain variable region has an amino acid sequence as shown in SEQ ID NO: 4.

4 . The monoclonal antibody specifically binding to a CAR molecule according to claim 1 , wherein the heavy chain variable region has an amino acid sequence as shown in SEQ ID NO: 8.

5 . The monoclonal antibody specifically binding to a CAR molecule according to claim 1 , wherein the light chain variable region has an amino acid sequence as shown in SEQ ID NO: 4 and the heavy chain variable region of the monoclonal antibody has an amino acid sequence as shown in SEQ ID NO: 8.